1. Comparison of two regimens for patients with thyroid‑associated ophthalmopathy receiving intravenous methyl prednisolone: A single center prospective randomized trial
- Author
-
Longyi Zeng, Shuo Lin, Jing-Ren Li, Yina Wang, Xixiang Tang, Li Zhou, Jiong Shu, Qiongli Yin, Yanming Chen, Panwei Mu, Bilian Zhu, and Man-man Wang
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Single Center ,Gastroenterology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Immunology and Microbiology (miscellaneous) ,Randomized controlled trial ,law ,Internal medicine ,Medicine ,Adverse effect ,Response rate (survey) ,business.industry ,Articles ,General Medicine ,Regimen ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cohort ,Biomarker (medicine) ,business ,Glucocorticoid ,medicine.drug - Abstract
Intravenous (i.v.) glucocorticoid is recommended for active moderate-to-severe thyroid-associated ophthalmopathy (TAO). However, the details of the treatment schedule are still debatable. The present prospective randomized trial was performed to compare clinical outcomes and serum cytokines between the two regimens. A cohort of 90 patients with active moderate-to-severe TAO was randomized to receive i.v. methyl prednisolone on a weekly protocol or daily scheme. The response rate was evaluated at the 12-week follow-up visit. Serum interleukin (IL)-2, IL-6 and IL-17 levels were measured in 160 patients with TAO, 60 patients with isolated Graves' disease (GD) and 60 normal control (NC) at baseline, as well as patients with active moderate-to-severe TAO at the 12(th) week after treatment. The daily scheme had a higher response rate than the weekly protocol without a significant difference (77.8 vs. 63.6%, P>0.05). No major adverse events were recorded under either regimen. Overall, minor events were more common on the daily scheme (11.36 vs. 4.35%, P
- Published
- 2020